Boehringer Ingelheim acquires all ViraTherapeutics shares to develop next-gen viral-based therapies

Boehringer Ingelheim has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies.

ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus with modified glycoprotein), which is being investigated alone and in combination with other therapies. The total transaction value of EUR 210 million is based on an option and share purchase agreement signed between the companies in Aug. 2016.

The lead investigational candidate leveraging the platform, VSV-GP, has shown promising results in pre-clinical models, especially in combination with key immune modulatory principles Boehringer Ingelheim is developing.

ViraTherapeutics was a portfolio company of the two venture investors EMBL Ventures and the Boehringer Ingelheim Venture Fund (BIVF).

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

Nearly half of cancer patients and survivors in the United States face medical debt so crushing that it has sparked a relatively new focus within oncology: financial toxicity.

July 11, 2025

Vol.51 No.27

By Claire Marie Porter

Conversation with The Cancer Letter

HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine

The U.S. Department of Health and Human Services last week cancelled a scheduled meeting of the U.S. Preventive Services Task Force, a 16-member panel that writes guidelines for screening and prevention based on the principles of evidence-based medicine.

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

Unless you were sleeping under a rock, you are aware of the coordinated attacks on Iran’s nuclear facilities by Israel and the United States.

July 11, 2025

Vol.51 No.27

By Robert Peter Gale

Clinical Trials & Tribulations

An overlooked immune cell population may offer new direction for cell and gene therapy

Cell and gene therapies have made incredible strides over the past decade. The 2024 FDA approvals of the first T-cell receptor therapy for the treatment of metastatic synovial sarcoma and the first tumor-infiltrating lymphocyte therapy for the treatment of unresectable or metastatic melanoma mark a significant turning point for solid tumor treatment.xxx:more

July 11, 2025

Vol.51 No.27

By Arthur Machlenkin

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

The intersection of diabetes, obesity and cancer represents an important and underappreciated challenge in medicine. Apart from smoking, overweight is now the leading modifiable risk factor for cancer. With the global epidemic of overweight and diabetes driving cancer incidence across multiple organ sites, understanding the metabolic underpinnings of this relationship has never been more critical.

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

The Pazdurs in their garden with their dog, Cleo. The dog’s full name is Cleopatra, Queen of Denial.In 1999, Rick Pazdur went in for a “perfunctory” final interview at FDA. Thinking it would only take a few minutes, his wife, Mary, decided to wait and have a quick cup of coffee at a nearby restaurant—Hooters.

July 11, 2025

Vol.51 No.27

By Katie Goldberg

Boehringer Ingelheim acquires all ViraTherapeutics shares to develop next-gen viral-based therapies

YOU MAY BE INTERESTED IN

First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

An overlooked immune cell population may offer new direction for cell and gene therapy

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

Renew today!

Subscriber content

Never miss an issue!

Login

Boehringer Ingelheim acquires all ViraTherapeutics shares to develop next-gen viral-based therapies

YOU MAY BE INTERESTED IN

First-ever financial toxicity tumor board aims to change the standard of careResearchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

HHS seems poised to exert control over USPSTFRansohoff: The task force is the pinnacle of evidence-based medicine

Understanding the impact of the Israeli-U.S. attacks on Iran’s nuclear facilities

An overlooked immune cell population may offer new direction for cell and gene therapy

Unraveling connections between diabetes and cancer: Insights from metabolism research at City of Hope

Rick and Mary Pazdur on facing “the other side of the stethoscope”A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology

Never miss an issue!

Login

First-ever financial toxicity tumor board aims to change the standard of care
Researchers focus on debt as a side effect of cancer, treatment amid cuts to Medicaid, NCI

HHS seems poised to exert control over USPSTF
Ransohoff: The task force is the pinnacle of evidence-based medicine

Rick and Mary Pazdur on facing “the other side of the stethoscope”
A few months before Mary died of ovarian cancer, the couple shared how this experience shaped their perspectives on oncology